Drug intelligence / Profile preview

ropivacaine + ketorolac + morphine sulfate

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intraarticular, Periarticular, Infusion

Overview

A multimodal analgesic combination used for postoperative pain management. This combination works through multiple mechanisms: ropivacaine blocks nerve conduction by inhibiting sodium channels, ketorolac reduces inflammation by inhibiting prostaglandin synthesis, and morphine provides central analgesic effects through mu-opioid receptors. Commonly used for intra-articular or periarticular administration following orthopedic surgeries.

Targets

NaV (Voltage-gated sodium channels)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ropivacaine + ketorolac + morphine sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ropivacaine + ketorolac + morphine sulfate.

Explore the full profile